secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2026-01-15T23:59:59+00:00
Accession:  0001493152-26-002422
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma grants stock options to directors, officers, and consultant under 2025 Plan
--------------------------------------------------------------------------------

- Non-qualified stock options granted to 7 directors, 2 executive officers, and 1 consultant, vesting over 1-2 years.
- Vesting: 50% on Jan 9, 2027; remaining 50% in 8 quarterly installments starting Mar 31, 2027.
- Dr. Roger Kornberg receives 24,615 options (plus $50,000 cash award for SAB chair); James Martin and Sam Lee each receive 49,229.
- Directors (excluding executives) each receive 16,410 options; consultant receives 40,000 options.
- Options have 10-year term, exercise price set at Jan 8, 2026 closing price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226002422/0001493152-26-002422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226002422/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-002422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer